Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin--Insights From the ENGAGE AF-TIMI 48 Trial.

@article{Shimada2015EffectsOR,
  title={Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin--Insights From the ENGAGE AF-TIMI 48 Trial.},
  author={Yuichi J. Shimada and Takeshi Yamashita and Yukihiro Koretsune and Tetsuya Kimura and Kenji Abe and Shunichi Sasaki and Michele Mercuri and Christian Thomas Ruff and Robert P Giugliano},
  journal={Circulation journal : official journal of the Japanese Circulation Society},
  year={2015},
  volume={79 12},
  pages={2560-7}
}
BACKGROUND In 21,105 patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial, edoxaban was non-inferior to warfarin in preventing thromboembolic events while reducing bleeding. We compared results in Japan with the rest of East Asia (EA), including China, Korea, and Taiwan. METHODSANDRESULTS We compared baseline characteristics, time-in-therapeutic range (TTR) for warfarin, and outcomes (efficacy: stroke or systemic embolic events [SEE], safety: major bleeding). Interaction P values… CONTINUE READING
11 Citations
22 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Similar Papers

Loading similar papers…